Acetaminophen: A hazard to immunotherapy

Najeebullah,; Ali, Maria Ameer; Naveed, Rida; Khatri, Govinda; Priya,; Hasan, Mohammad Mehedi

doi:10.1016/j.amsu.2022.104272

Cited by 2 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acetaminophen is a widely used FDA approved drug for pain and fever relief though the mechanism remains elusive. It may achieve its effects by crossing the blood-brain barrier and acting on the central serotonergic system ( 71 ). However, this view is contested by other assertions that acetaminophen blocks cyclooxygenase (COX) enzymes implicated in the formation of prostaglandins, molecules that control inflammation and pain.…”

Section: Interventions and Circumstances To Consider Avoiding With Ic...mentioning

confidence: 99%

Readily available drugs and other interventions to potentially improve the efficacy of immune checkpoint blockade in cancer

Coleman,

Mascialino,

Panjwani

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

To improve the efficacy of immune checkpoint inhibitors (ICIs) for cancer treatment, various strategies, including combination therapies with repurposed drugs, are being explored. Several readily available interventions with potential to enhance programmed death 1 (PD-1) blockade have been identified. However, these interventions often remain overlooked due to the lack of financial incentives for their development, making them financial orphans. This review summarizes current knowledge regarding off-label drugs, supplements, and other readily available interventions that could improve the efficacy of PD-1 blockade. The summary of each intervention includes the proposed mechanism of action for combination with checkpoint inhibitors and data from animal and human studies. Additionally, we include summaries of common interventions to be avoided by patients on PD-1 blockade. Finally, we present approaches for conducting further studies in patients, with the aim of expediting the clinical development of these interventions. We strive to increase awareness of readily available combination therapies that may advance cancer immunotherapy and help patients today.

show abstract

Section: Interventions and Circumstances To Consider Avoiding With Ic...mentioning

confidence: 99%